Advertisement

Topics

Pfizer locks down US approval for Besponsa

04:30 EDT 18 Aug 2017 | BioPharmaDive

The drug is the first CD22-targeting antibody-drug candidate to gain approval for a specific population of acute lymphoblastic leukemia patients.

Original Article: Pfizer locks down US approval for Besponsa

NEXT ARTICLE

More From BioPortfolio on "Pfizer locks down US approval for Besponsa"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...